Corporate ActionAug 4, 2026, 05:03 PM
Decoy Therapeutics to vote on warrant exercise, authorized share reduction
AI Summary
Decoy Therapeutics Inc. announced a Special Meeting of Stockholders on September 14, 2026, to vote on key corporate actions. These include approving the issuance of shares upon the exercise of Milestone Warrants from a recent private placement, which could bring in an additional $17.5 million, and reducing the number of authorized common shares. The Board of Directors unanimously recommends stockholders vote in favor of all proposals.
Key Highlights
- Special Meeting of Stockholders scheduled for September 14, 2026, to vote on three proposals.
- Warrant Exercise Proposal seeks approval for issuing up to 2,961,085 shares from Milestone Warrants.
- Approval enables potential $17.5 million in additional gross proceeds from Milestone Warrant exercise.
- Authorized Share Proposal aims to reduce authorized common stock by 10,000,000 to 90,000,000 shares.
- Private Placement on June 29, 2026, generated approximately $3.5 million in gross proceeds.
- Board of Directors unanimously recommends voting "FOR" all three proposals.
Price Impact
More from DCOY
More in Corporate Action